Elizabeth Colston

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

April W. Armstrong, Melinda Gooderham, Richard B. Warren et al. · Journal of the American Academy of Dermatology · 2022 · 347 citations · Full text

Medicine, Dermatology, Pharmacotherapy +7

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Bruce Strober, Diamant Thaçi, Howard Sofen et al. · Journal of the American Academy of Dermatology · 2022 · 279 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*

Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende et al. · Critical Care Medicine · 2019 · 245 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende et al. · Intensive Care Medicine · 2019 · 194 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12

Soluble receptor‐resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor.

Elizabeth Colston, Vincent R. Racaniello · The EMBO Journal · 1994 · 101 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16